Ventyx Biosciences Raises $ 114 Million Funding Led by venBio Partners to Advance Various Immunology Programs

ENCINITAS, California, Mar. 9, 2021 / PRNewswire / – Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biotechnology company that is developing a pipeline of immune modulators to treat inflammatory and autoimmune diseases, announced today hui the completion of a $ 114 million equity financing led by venBio Partners alongside new investors including Third Point, RTW Investments, LP, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital (a Citadel company), Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners United States, Cormorant Asset Management and the participation of founding investor New Science Ventures. As part of the funding, Richard gaster and Aaron Royston from venBio Partners and Jigar choksey from Third Point will join Ventyx’s board of directors.

“We are extremely proud to have the support of such distinguished investors who share our enthusiasm, dedication and vision to build a world-class immunology company,” said Raju mohan, Chairman and CEO of Ventyx. “The additional capital will allow us to accelerate our clinical development programs while simultaneously expanding our portfolio of small molecule therapeutics with best-in-class potential for patients with inflammatory and autoimmune diseases. We have assembled a union of experienced investors who can support the long-term growth and development of our extensive immune modulator pipeline. “

The portfolio of potent and selective small molecule drug candidates, discovered in-house and wholly owned by Ventyx, targets multiple indications in the field of immunology, including gastrointestinal and dermatological diseases. The company’s pipeline combines the clinical stage programs of three companies founded by Raju mohan and new scientific enterprises:

  1. A selective fabric S1P1R modulator of inflammatory bowel disease (IBD) and other indications developed by Oppilan Pharma;
  2. A selective allosteric TYK2 an inhibitor, developed by Ventyx, which is expected to demonstrate high efficacy and therapeutic utility in a wide range of immunological disorders; and
  3. the NLRP3 inhibitor program, created by Zomagen. The first candidate for this program will enter the clinic in the second semester of this year.

In addition, the company is leveraging its world-class drug discovery platform to advance preclinical programs against other biologically relevant targets involved in inflammatory diseases and difficult-to-treat autoimmune diseases.

“The Ventyx team has done an extraordinary job advancing high-quality clinical drug candidates rapidly and efficiently against compelling biological targets,” said Richard gaster by venBio. “We are following the I&I space closely and are delighted to bring these assets together into one exceptional company and lead the current fundraising round. We look forward to supporting Ventyx’s efforts to bring meaningful new treatments to patients.

“We are delighted to call on such a distinguished group of healthcare investors to support the development of the Company’s innovative immunology programs, and we welcome Rich, Aaron and Jigar to the Board of administration ”, added Somu Subramaniam new scientific ventures.

About Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. is a clinical-stage biotechnology company developing a broad portfolio of potent and selective small molecule drug candidates for treating inflammatory diseases and autoimmune disorders. Ventyx Biosciences combines the assets of three formerly independent, asset-centric companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting the NLRP3 inflammasome, and original Ventyx Biosciences, targeting TYK2. The diversified portfolio of the new joint entity includes first-class, highly differentiated clinical-stage and pre-clinical programs focused on high value-added targets.

Ventyx is headquartered at Encinitas, California. For more information on Ventyx, please visit

About venBio partners

venBio Partners is a life sciences investment firm that partners with industry leaders to create and invest in innovative drugs and technologies, with a focus on new therapies for medical needs not satisfied. See

About New Science Ventures

New Science Ventures, LLC (NSV) is a New YorkA venture capital firm that invests in companies using cutting edge science to create and build large companies in the life sciences and information technology industries. NSV was founded in 2004 by Somu Subramaniam, managing partner, and invested approximately $ 800 million in start-up and start-up companies located in United States and European. For more information, please visit


Chris Krueger
Ventyx Biosciences, Inc.
(858) 945-2393
[email protected]

Investor Relations and Media Contact

Juniper hint
Amy conrad
(858) 914-1962
[email protected]

SOURCE Ventyx Biosciences, Inc.

About Paul Cox

Check Also

Congress rushes to strike coronavirus deal as shutdown looms

Congressional leaders are rushing to finalize and pass a $ 900 billion coronavirus relief deal …